The FDA accepted the BLA for ivonescimab plus chemotherapy for patients with EGFR-mutated non-small cell lung cancer post-TKI ...
ProMIS Neurosciences Inc. (Nasdaq: PMN) (“ProMIS” or the “Company”), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vaccines targeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results